Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more
Mayne Pharma Group Limited (MAYNF) - Net Assets
Latest net assets as of June 2025: $370.28 Million USD
Based on the latest financial reports, Mayne Pharma Group Limited (MAYNF) has net assets worth $370.28 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.01 Billion) and total liabilities ($644.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $370.28 Million |
| % of Total Assets | 36.5% |
| Annual Growth Rate | 19.71% |
| 5-Year Change | -52.01% |
| 10-Year Change | -1.58% |
| Growth Volatility | 101.51 |
Mayne Pharma Group Limited - Net Assets Trend (2007–2025)
This chart illustrates how Mayne Pharma Group Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mayne Pharma Group Limited (2007–2025)
The table below shows the annual net assets of Mayne Pharma Group Limited from 2007 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $370.28 Million | -18.47% |
| 2024-06-30 | $454.19 Million | -28.40% |
| 2023-06-30 | $634.36 Million | +13.86% |
| 2022-06-30 | $557.12 Million | -27.79% |
| 2021-06-30 | $771.58 Million | -25.97% |
| 2020-06-30 | $1.04 Billion | +2.78% |
| 2019-06-30 | $1.01 Billion | -17.90% |
| 2018-06-30 | $1.24 Billion | -5.89% |
| 2017-06-30 | $1.31 Billion | +248.84% |
| 2016-06-30 | $376.22 Million | +16.77% |
| 2015-06-30 | $322.20 Million | +102.29% |
| 2014-06-30 | $159.27 Million | +31.75% |
| 2013-06-30 | $120.89 Million | +295.06% |
| 2012-06-30 | $30.60 Million | +26.58% |
| 2011-06-30 | $24.17 Million | -5.38% |
| 2010-06-30 | $25.55 Million | +231.63% |
| 2009-06-30 | $7.70 Million | -32.65% |
| 2008-06-30 | $11.44 Million | -21.19% |
| 2007-06-30 | $14.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mayne Pharma Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 103914912800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.23 Billion | 331.09% |
| Other Comprehensive Income | $185.29 Million | 50.04% |
| Other Components | $1.00 | 0.00% |
| Total Equity | $370.28 Million | 100.00% |
Mayne Pharma Group Limited Competitors by Market Cap
The table below lists competitors of Mayne Pharma Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bonava AB (publ)
ST:BONAV-B
|
$183.49 Million |
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM
|
$183.49 Million |
|
Hefei Department Store Group Co Ltd
SHE:000417
|
$183.52 Million |
|
SANIONA AB (PUBL)
F:30S
|
$183.59 Million |
|
Seven West Media Limited
PINK:WANHY
|
$183.39 Million |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
$183.33 Million |
|
Bonava AB B
LSE:0RHA
|
$183.30 Million |
|
Binh Dinh Pharmaceutical and Medical Equipment JSC
VN:DBD
|
$183.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mayne Pharma Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 454,188,000 to 370,283,000, a change of -83,905,000 (-18.5%).
- Net loss of 93,836,000 reduced equity.
- Share repurchases of 148,000 reduced equity.
- Other comprehensive income increased equity by 11,318,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-93.84 Million | -25.34% |
| Share Repurchases | $148.00K | -0.04% |
| Other Comprehensive Income | $11.32 Million | +3.06% |
| Other Changes | $-1.24 Million | -0.33% |
| Total Change | $- | -18.47% |
Book Value vs Market Value Analysis
This analysis compares Mayne Pharma Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | $4.71 | $4.19 | x |
| 2008-06-30 | $2.15 | $4.19 | x |
| 2009-06-30 | $1.45 | $4.19 | x |
| 2010-06-30 | $2.87 | $4.19 | x |
| 2011-06-30 | $2.27 | $4.19 | x |
| 2012-06-30 | $2.87 | $4.19 | x |
| 2013-06-30 | $5.49 | $4.19 | x |
| 2014-06-30 | $4.97 | $4.19 | x |
| 2015-06-30 | $8.75 | $4.19 | x |
| 2016-06-30 | $9.00 | $4.19 | x |
| 2017-06-30 | $17.84 | $4.19 | x |
| 2018-06-30 | $16.77 | $4.19 | x |
| 2019-06-30 | $13.66 | $4.19 | x |
| 2020-06-30 | $13.57 | $4.19 | x |
| 2021-06-30 | $9.78 | $4.19 | x |
| 2022-06-30 | $6.86 | $4.19 | x |
| 2023-06-30 | $7.35 | $4.19 | x |
| 2024-06-30 | $5.70 | $4.19 | x |
| 2025-06-30 | $4.68 | $4.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mayne Pharma Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.99%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 2.74x
- Recent ROE (-25.34%) is below the historical average (-9.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -12.57% | -1301.80% | 0.01x | 1.07x | $-3.28 Million |
| 2008 | -30.36% | -423.09% | 0.07x | 1.02x | $-4.62 Million |
| 2009 | -48.82% | -361.71% | 0.13x | 1.04x | $-4.53 Million |
| 2010 | 12.73% | 8.78% | 0.52x | 2.78x | $698.14K |
| 2011 | 6.95% | 3.44% | 0.91x | 2.22x | $-738.40K |
| 2012 | 20.11% | 12.05% | 0.95x | 1.76x | $3.09 Million |
| 2013 | -2.35% | -3.46% | 0.35x | 1.93x | $-14.93 Million |
| 2014 | 13.37% | 14.97% | 0.53x | 1.67x | $5.36 Million |
| 2015 | 2.50% | 5.53% | 0.27x | 1.70x | $-23.33 Million |
| 2016 | 10.27% | 14.03% | 0.17x | 4.28x | $980.10K |
| 2017 | 6.79% | 15.49% | 0.30x | 1.47x | $-41.82 Million |
| 2018 | -10.92% | -25.32% | 0.29x | 1.49x | $-256.63 Million |
| 2019 | -27.87% | -53.60% | 0.32x | 1.62x | $-381.64 Million |
| 2020 | -8.94% | -20.32% | 0.25x | 1.76x | $-196.54 Million |
| 2021 | -27.13% | -52.06% | 0.27x | 1.90x | $-285.26 Million |
| 2022 | -37.09% | -133.30% | 0.12x | 2.28x | $-265.96 Million |
| 2023 | 18.48% | 63.87% | 0.15x | 1.97x | $53.81 Million |
| 2024 | -38.36% | -44.89% | 0.34x | 2.52x | $-219.65 Million |
| 2025 | -25.34% | -22.99% | 0.40x | 2.74x | $-130.86 Million |
Industry Comparison
This section compares Mayne Pharma Group Limited's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,254,633,395
- Average return on equity (ROE) among peers: -3.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mayne Pharma Group Limited (MAYNF) | $370.28 Million | -12.57% | 1.74x | $183.45 Million |
| Accendra Health Inc (ACH) | $314.40 Million | 8.91% | 1.75x | $22.90K |
| Arjo AB (publ) (ARRJF) | $6.88 Billion | 10.78% | 1.12x | $491.29 Million |
| Cardinal Health Inc (CAH) | $255.60 Million | 13.15% | 1.57x | $50.81 Billion |
| Cencora Inc. (COR) | $4.01 Billion | 11.02% | 2.01x | $62.31 Billion |
| Cosmos Health Inc. (COSM) | $36.04 Million | -51.45% | 0.83x | $8.90 Million |
| EDAP TMS SA (EDAP) | $50.05 Million | 1.40% | 0.54x | $115.72 Million |
| Empro Group Inc. Ordinary shares (EMPG) | $741.21K | -42.90% | 4.10x | $9.16 Million |
| Energy Management International Inc (ENMI) | $-362.21K | 0.00% | 0.00x | $383.13K |
| Exlites Holdings International Inc (EXHI) | $-84.27 | 0.00% | 0.00x | $574.58K |
| Galenica AG (GALNF) | $999.54 Million | 12.50% | 1.21x | $3.75 Billion |